This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

ReFacto AF (moroctocog alfa) Prescribing Information for Great Britain click here. ReFacto AF (moroctocog alfa) Prescribing Information for Northern Ireland click here.
BeneFIX (nonacog alfa) Prescribing Information for Great Britain
click here. BeneFIX (nonacog alfa) Prescribing Information for Northern Ireland click here.

Adverse event reporting information can be found at the bottom of the page.​​​​​

Pfizer helps to find practical approaches to haemophilia care through partnering with various organisations.

Pfizer has partnered with various organisations to help find practical approaches to haemophilia care

  • Pfizer is committed to the improvement of long-term outcomes for people with haemophilia and the support they receive to manage their conditions
  • Through scientific collaboration and long-term investment in new haemophilia therapies, we aim to advance the treatment and address the unmet needs of people with haemophilia

Treatment of haemophilia

Haemophilia is quite rare; about 1 in 10,000 people are born with it1. A primary aim of care in haemophilia is to prevent and treat bleeding with the deficient clotting factor2:

  • On-demand: Treatment given at the time of clinically evident bleeding or before, during or after an activity or intervention likely to increase the risk of bleeding
  • Prophylaxis: Treatment given regularly in order to prevent anticipated bleeding

Milestones in Pfizer Haemophilia

Pfizer continue to invest in the research and development of haemophilia treatment. View our Pfizer timeline of milestones in haemophilia, spanning from the early 1990's.

Explore more

What is haemophilia?

Find out more

Explore our range of educational materials for children with haemophilia

Click here

  1. World Federation of Hemophilia. What is Hemophilia? Available at: (Accessed January 2020).
  2. Srivastava A et al. Guidelines for the management of hemophilia. 2013;19, e1-e47
  3. Funding Universe. Genetics Institute, Inchistory. Available at: (Accessed January 2020).
  4. CenterWatch. BeneFIX(coagulation Factor IX (recombinant)). Available at: (Accessed January 2020)
  5. Kelley B et al. An improved manufacturing process for Xyntha/ ReFactoAF. Haemophilia 2010;16(5):717–725.
  6. ReFacto AF® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.
  7. BioSpace. Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX, published 26th March 2007. Available at: (Accessed January 2020).
  8. Lambert T et al. Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007;13(3):233–243.
  9. European Medicines Agency. Assessment report for ReFacto AF. 2009. Doc ref: EMEA/55167/2009. Available at: (Accessed October 2020).
  10. BeneFIX® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.
  11. ​​​​​​​European Medicines Agency. BeneFIX EPAR – procedural steps taken and scientific information after the authorisation. Available at: (Accessed October 2020).
  12. The Rare Disease Consortium. Available at: (Accessed January 2020).
  13. Electronic medicines compendium. ReFacto AF Patient Information Leaflet. Available at:
  14. Electronic medicines compendium. BeneFIX Patient Information Leaflet. Available at:
PP-BEN-GBR-0568. October 2021


For your patients with haemophilia B

Find out more

ReFacto AF

For your patients with haemophilia A

Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?